Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Tretinoin × Other solid neoplasm × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 47 Myeloid 13 Plasma cell 9 Dermatologic 7 Thoracic 5 Lymphoid 5 CNS 5 Gastrointestinal 4 Classical hematology 4 Breast 4 Tumor-Agnostic 3 Genitourinary 3 Sarcoma 1 Other solid neoplasm 1 NET 1 Head & Neck 1 Gynecologic 1 Endocrine 1

Conditions

Oligometastatic Disease 1

Interventions

Cisplatin 134 Carboplatin 114 pembrolizumab 113 Paclitaxel 94 Injections 90 Pemetrexed 87 Gemcitabine 80 Irinotecan 70 Cyclophosphamide 65 Docetaxel 61 Nivolumab 60 Bevacizumab 56 Fluorouracil 45 Oxaliplatin 44 Capecitabine 42 atezolizumab 41 Leucovorin 39 tislelizumab 37 Etoposide 36 toripalimab 30 fludarabine 28 Ipilimumab 28 Topotecan 26 Radiotherapy 25 Drug Therapy 25 durvalumab 24 Early Intervention, Educational 24 Vincristine 23 Sorafenib 22 Filgrastim 22

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06439888 2025-12-01

LySATRA

Gustave Roussy, Cancer Campus, Grand Paris

Phase 1/2 Recruiting

Other solid neoplasm

Oligometastatic Disease

Data powered by HemOnc (CC BY 4.0) Colophon ⚡